Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Mar
04
Today In Oncology
Dietary Influence on Leukemia and Lymphoma Progression
Is Advanced Stage Follicular Lymphoma Curable?
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo